Moderna's CMV trial offers further upside - UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St to open higher on oil retreat, tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
Moderna (MRNA) downgraded as HSBC skeptical on medium term INT Phase 3 data readouts
February 26, 2024 9:33 AM ESTHSBC analysts cut Moderna (NASDAQ: MRNA) to Reduce from Hold in a note Monday, raising the price target to $86 from $75 per share.
The firm said Moderna's outlook for 2024 is underpinned by prospects for its COVID-19 vaccine revenue and RSV launch. They note there are two... More
